Treatment | Trial | ED50 (95% CI) | Curve Steepness | Maximal Response |
---|---|---|---|---|
nmol | ||||
p-BPB (n= 5) | 1 | 20.20 (18.27–22.34) | 1.53 ± 0.06 | 70 ± 4 |
2 | 25.01 (21.88–28.60) | 1.40 ± 0.07 | 40 ± 44-a | |
Indomethacin (n = 4) | 1 | 22.90 (20.21–25.96) | 1.64 ± 0.17 | 71 ± 2 |
2 | 27.96 (23.04–33.93) | 1.36 ± 0.02 | 49 ± 14-a | |
Esculetin (n = 4) | 1 | 30.58 (29.33–31.88) | 1.58 ± 0.09 | 72 ± 5 |
2 | 32.66 (30.12–35.42) | 1.79 ± 0.25 | 50 ± 44-a | |
SQ-29548 (n = 3) | 1 | 23.80 (21.25–26.65) | 1.55 ± 0.06 | 68 ± 3 |
2 | 23.43 (20.19–27.19) | 1.61 ± 0.19 | 57 ± 24-a | |
L-660711 (n = 3) | 1 | 27.56 (23.08–32.91) | 1.46 ± 0.25 | 69 ± 2 |
2 | 36.39 (33.38–39.67) | 1.32 ± 0.02 | 55 ± 24-a |
Trial 1 (control). Trial 2 (treated with an inhibitor or a blocker). Data for ED50 are given as the geometric mean with a 95% CI. The curve steepness coefficient and the maximal vasoconstrictor response are expressed as arithmetic means with S.E. ED50 and curve steepness coefficient are determined from nonlinear regression analysis of dose-response data.
↵4-a Significantly different from trial 1 in each treatment group (paired t test, P < .05).